ZA969212B - (-)cis-6(S)-phenyl-5(R)[4-(2-pyrrolidin-1-yl ethoxy)phenyl]-5,6,7,8,-tetrahydronaphthalen-2-ol-D-tartrate. - Google Patents
(-)cis-6(S)-phenyl-5(R)[4-(2-pyrrolidin-1-yl ethoxy)phenyl]-5,6,7,8,-tetrahydronaphthalen-2-ol-D-tartrate.Info
- Publication number
- ZA969212B ZA969212B ZA9609212A ZA969212A ZA969212B ZA 969212 B ZA969212 B ZA 969212B ZA 9609212 A ZA9609212 A ZA 9609212A ZA 969212 A ZA969212 A ZA 969212A ZA 969212 B ZA969212 B ZA 969212B
- Authority
- ZA
- South Africa
- Prior art keywords
- phenyl
- tetrahydronaphthalen
- pyrrolidin
- tartrate
- cis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pregnancy & Childbirth (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US612595P | 1995-11-02 | 1995-11-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA969212B true ZA969212B (en) | 1998-05-04 |
Family
ID=21719433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA9609212A ZA969212B (en) | 1995-11-02 | 1996-11-01 | (-)cis-6(S)-phenyl-5(R)[4-(2-pyrrolidin-1-yl ethoxy)phenyl]-5,6,7,8,-tetrahydronaphthalen-2-ol-D-tartrate. |
Country Status (43)
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
GB9703109D0 (en) * | 1997-02-14 | 1997-04-02 | Smith & Nephew | Compositions |
ATE265853T1 (de) * | 1998-06-16 | 2004-05-15 | Pfizer Prod Inc | Kombinationstherapeutika, enthaltend einen selektiven östrogenrezeptormodulator und prostaglandin e2 |
ID26726A (id) * | 1998-06-16 | 2001-02-01 | Pfizer Prod Inc | Kombinasi terapeutik untuk kelemahan muskuloskeletal |
AR018869A1 (es) * | 1998-06-16 | 2001-12-12 | Pfizer Prod Inc | Composicion farmaceutica, su uso para la preparacion de medicamentos y estuche que la contiene |
YU26700A (sh) * | 1999-05-24 | 2002-06-19 | Pfizer Products Inc. | Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin |
CO5271696A1 (es) * | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para reducir la morbilidad y el riesgo de mortalidad |
CO5271697A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona |
CO5251465A1 (es) | 2000-01-26 | 2003-02-28 | Pfizer Prod Inc | Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol |
CZ20023223A3 (cs) | 2000-04-07 | 2003-12-17 | Pfizer Products Inc. | Metabolity s agonisty/antagonisty estrogenu |
US20020013327A1 (en) * | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
DE60124616T2 (de) | 2000-05-08 | 2007-09-13 | Pfizer Products Inc., Groton | Enzymatische Spaltung von selektiven Modulatoren des Östrogenrezeptors |
IL145838A (en) * | 2000-10-16 | 2008-11-03 | Pfizer Prod Inc | Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis |
TWI303990B (en) | 2000-10-17 | 2008-12-11 | Pfizer Prod Inc | New use of estrogen agonists/antagonists for improving vascular health |
AU781168B2 (en) * | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
AU2756602A (en) * | 2001-04-25 | 2002-10-31 | Pfizer Products Inc. | Methods and kits for treating depression or preventing deterioration of cognitive function |
JP2004531537A (ja) | 2001-05-01 | 2004-10-14 | ファイザー・プロダクツ・インク | 一様な薬剤分布と効力を有する低用量製薬組成物の製造方法 |
CN1599606A (zh) * | 2001-07-31 | 2005-03-23 | 辉瑞产品公司 | 包含雌激素激动剂/拮抗剂、雌激素与孕激素组合的药物组合物、试剂盒和方法 |
RU2317104C2 (ru) * | 2001-09-24 | 2008-02-20 | Импиэриэл Инноувейшнс Лимитид | Способ модификации пищевого поведения и применение pyy или его агониста в качестве средства для модификации пищевого поведения |
RS80604A (en) * | 2002-03-28 | 2007-02-05 | Pfizer Products Inc., | Purified lasoxifene and a method for purification of racemic lasofoxifene by recrystallization |
PA8576201A1 (es) * | 2002-07-10 | 2004-05-26 | Pfizer Prod Inc | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco |
US7799273B2 (en) | 2004-05-06 | 2010-09-21 | Smp Logic Systems Llc | Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes |
US7444197B2 (en) | 2004-05-06 | 2008-10-28 | Smp Logic Systems Llc | Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes |
CA2571482A1 (en) * | 2004-06-21 | 2005-12-29 | Pharmacia & Upjohn Company Llc | Pyk2 inhibitors for stimulation of osteoblast function |
MXPA06015112A (es) * | 2004-06-30 | 2007-02-08 | Lilly Co Eli | D-tartrato de 1-(indol-6-carbonil-d-fenilglicinil)-4-(1-metilpiperidin-4-il) piperazina. |
CA2611035C (en) * | 2005-06-22 | 2010-09-14 | Pfizer Products Inc. | Stereoselective hydrogenation process for preparing cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-2-methoxy-5,6,7,8-tetrahydronaphthalene hydrochloride |
CZ2007373A3 (cs) * | 2007-05-29 | 2008-12-10 | Zentiva, A. S | Zpusob prípravy lasofoxifenu |
WO2010125578A2 (en) | 2009-04-29 | 2010-11-04 | Glenmark Generics Limited | A process for the preparation of lasofoxifene tartrate |
KR101149529B1 (ko) | 2009-09-11 | 2012-05-25 | 한국화학연구원 | 인덴온 유도체 및 이를 포함하는 약학적 조성물 |
CN103113323B (zh) * | 2013-02-05 | 2015-11-11 | 南京华威医药科技开发有限公司 | 酒石酸拉索昔芬中间体的制备方法 |
CA3040266A1 (en) | 2016-10-11 | 2018-05-24 | Duke University | Lasofoxifene treatment of er+ breast cancer |
US11497730B2 (en) | 2018-04-10 | 2022-11-15 | Duke University | Lasofoxifene treatment of breast cancer |
KR20220115062A (ko) | 2021-02-09 | 2022-08-17 | (주)오스티오뉴로젠 | 크로몬 구조의 화합물을 포함하는 골다공증의 예방 및 치료용 약학적 조성물 |
GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3234090A (en) * | 1962-09-10 | 1966-02-08 | Ciba Geigy Corp | Pharmaceutical compositions comprising saturated basic ethers |
US3522319A (en) * | 1964-01-23 | 1970-07-28 | Ciba Geigy Corp | Phenol substituted tetrahydronaphthalenes useful as estrogenics |
US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
-
1996
- 1996-04-10 UA UA98042214A patent/UA51676C2/uk unknown
- 1996-09-30 TW TW085111903A patent/TW518327B/zh not_active IP Right Cessation
- 1996-09-30 TW TW091125091A patent/TW581766B/zh not_active IP Right Cessation
- 1996-10-04 KR KR1019980703251A patent/KR19990067280A/ko not_active Application Discontinuation
- 1996-10-04 US US09/065,094 patent/US5948809A/en not_active Expired - Lifetime
- 1996-10-04 DE DE69629837T patent/DE69629837T2/de not_active Expired - Lifetime
- 1996-10-04 WO PCT/IB1996/001049 patent/WO1997016434A1/en active IP Right Grant
- 1996-10-04 BR BR9611436A patent/BR9611436A/pt not_active Application Discontinuation
- 1996-10-04 RO RO98-00926A patent/RO119829B1/ro unknown
- 1996-10-04 ES ES96931206T patent/ES2203713T3/es not_active Expired - Lifetime
- 1996-10-04 JP JP09517180A patent/JP3088020B2/ja not_active Expired - Lifetime
- 1996-10-04 DK DK96931206T patent/DK0876359T3/da active
- 1996-10-04 SK SK542-98A patent/SK282172B6/sk not_active IP Right Cessation
- 1996-10-04 PT PT96931206T patent/PT876359E/pt unknown
- 1996-10-04 CN CN96198048A patent/CN1067065C/zh not_active Expired - Lifetime
- 1996-10-04 TR TR1998/00783T patent/TR199800783T2/xx unknown
- 1996-10-04 IL IL12402796A patent/IL124027A/en not_active IP Right Cessation
- 1996-10-04 AT AT96931206T patent/ATE248827T1/de active
- 1996-10-04 CZ CZ19981320A patent/CZ287341B6/cs not_active IP Right Cessation
- 1996-10-04 AU AU69984/96A patent/AU708841B2/en not_active Expired
- 1996-10-04 HU HU9900087A patent/HU227521B1/hu unknown
- 1996-10-04 RU RU98110128/04A patent/RU2162465C2/ru active
- 1996-10-04 NZ NZ318498A patent/NZ318498A/xx not_active IP Right Cessation
- 1996-10-04 SI SI9630635T patent/SI0876359T1/xx unknown
- 1996-10-04 CA CA002236673A patent/CA2236673C/en not_active Expired - Lifetime
- 1996-10-04 PL PL96326498A patent/PL188633B1/pl unknown
- 1996-10-04 EP EP96931206A patent/EP0876359B1/en not_active Expired - Lifetime
- 1996-10-11 GT GT199600085A patent/GT199600085A/es unknown
- 1996-10-23 AR ARP960104862A patent/AR004078A1/es active IP Right Grant
- 1996-10-29 HR HR960503A patent/HRP960503B1/xx not_active IP Right Cessation
- 1996-10-30 TN TNTNSN96134A patent/TNSN96134A1/fr unknown
- 1996-10-30 MA MA24381A patent/MA23998A1/fr unknown
- 1996-10-30 DZ DZ960158A patent/DZ2114A1/fr active
- 1996-10-30 PE PE1996000753A patent/PE17698A1/es not_active Application Discontinuation
- 1996-10-30 EG EG95996A patent/EG21095A/xx active
- 1996-10-31 AP APAP/P/1996/000880A patent/AP713A/en active
- 1996-11-01 YU YU57896A patent/YU49123B/sh unknown
- 1996-11-01 ZA ZA9609212A patent/ZA969212B/xx unknown
- 1996-11-01 CO CO96057925A patent/CO4770967A1/es unknown
- 1996-11-04 UY UY24362A patent/UY24362A1/es unknown
-
1998
- 1998-04-16 IS IS4718A patent/IS1855B/is unknown
- 1998-04-29 OA OA9800046A patent/OA11009A/en unknown
- 1998-04-30 NO NO19981962A patent/NO310358B1/no not_active IP Right Cessation
- 1998-05-21 BG BG102474A patent/BG63943B1/bg unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA969212B (en) | (-)cis-6(S)-phenyl-5(R)[4-(2-pyrrolidin-1-yl ethoxy)phenyl]-5,6,7,8,-tetrahydronaphthalen-2-ol-D-tartrate. | |
AU4073997A (en) | 1,4-heterocyclic metallprotease inhibitors | |
AU2709900A (en) | Process for making 2,3-dihalopropanols | |
AU6016896A (en) | Heterocyclic compounds, their production and use | |
AU5652698A (en) | (2,3-dihydrobenzofuranyl)-thiazoles as phosphodiesterase inhibitors | |
AU1267895A (en) | Cable-saw machine | |
ZA969812B (en) | Novel quinoline derivatives. | |
AU2397997A (en) | Process for making 4,6-dihydroxypyrimidine | |
AU2280599A (en) | Transfer machine | |
AU1882295A (en) | Pyrrolo(2,3-(d))pyrimidine derivatives as antivirals | |
ZA979617B (en) | Novel heterocyclic compounds. | |
AU3255997A (en) | Process for preparing 1,3-alkanediols | |
AU2408495A (en) | Antirheumatic 1-alkyl-4-hydroxy-3-(thien-3-yl) 1,8-naphthyridin-2(1h)-ones | |
AU1513597A (en) | 1,25-dihydroxy-16,22,23-trisdehydro-cholecalciferol derivatives | |
AU2925095A (en) | Herbicidal 1,2,4,6-thiatriazines | |
AU2984695A (en) | 4-hydroxy-3-phenyl-indeno(1,2-b)pyridine-2(1h)-one derivatives as nmda antagonists | |
AU2137095A (en) | Heterocyclyl-1,3,4-thiadiazolyloxyacetamides | |
AU3026697A (en) | Process for preparing 4,6-diamino-resorcinol-dihydrochloride | |
AU1568895A (en) | Process for preparing 2,6-dichloropyridine | |
AU1385795A (en) | Substituted oxazolines | |
AU2224295A (en) | Game machine | |
AU1672799A (en) | Process and machine for fabricating trays provided with wells, and tray thus obtained | |
ZA969811B (en) | Novel quinoline derivatives. | |
ZA969810B (en) | Novel quinoline derivatives. | |
AU705798C (en) | Novel heterocyclic derivatives |